Results 121 to 130 of about 18,181 (226)
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways
Martin Schiestl,1 Markus Zabransky,2 Fritz Sörgel3,4 1Sandoz GmbH, Kundl, Austria; 2Sandoz Biopharmaceuticals, Hexal AG, Holzkirchen, Germany; 3Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany; 4Institute of ...
Schiestl M, Zabransky M, Sörgel F
doaj
Literature review of international biosimilar medicines
This report provides an update to the comprehensive literature search previously conducted on behalf of the Department of Health. To inform the activities related to GBMA Education's Biosimilar Education Grant these reviews examine all international and ...
Ward, M., Staff, K., Reuter Lange, S.
core
Adverse events reported in trials comparing biosimilar and reference insulins.
Adverse events reported in trials comparing biosimilar and reference insulins.
Carolyn Tieu (5117252) +4 more
core +1 more source
Exploring Stakeholder Perceptions and Experience of Biosimilar Insulin Switching: A Scoping Review
Background The option to switch patients to more cost‐effective biosimilar insulins has been available since 2014, and the market share for these medicines has been slowly increasing since then. This scoping review aimed to identify the current knowledge
Ben Hindley +4 more
doaj +1 more source
Biopharmaceuticals exhibit excellent therapeutic efficacy; however, their high cost remains a significant limitation. The introduction of biosimilars is expected to enhance market competition and reduce biopharmaceutical prices.
Tae-Kwon Kim, Tai-Hyun Kang
doaj +1 more source
Focus on biosimilar etanercept – bioequivalence and interchangeability
Fabrizio Cantini,1 Maurizio Benucci2 1Department of Rheumatology, Hospital of Prato, Prato, Italy; 2Rheumatology Unit, Hospital S. Giovanni di Dio, Florence, Italy Background: The recent approval of reference etanercept (re-ETN) biosimilars SB4, GP2015 ...
Cantini F, Benucci M
core
Background: treatment of erythropoietin (EPO) is essential in chronic kidney disease (CKD) patients to maintain optimal hemoglobin (Hb) level. Renogen is a biosimilar epoetin-α, and Eprex is the originator epoetin-α.
Ni Made Hustrini +3 more
doaj
Literature review of international biosimilar medicines: update March - May 2018
This report provides an update to the comprehensive literature search previously conducted on behalf of the Department of Health. To inform the activities related to GBMA Education's Biosimilar Education Grant these reviews examine all international and ...
Ward, M., Staff, K., Reuter Lange, S.
core

